Matches in Wikidata for { <http://www.wikidata.org/entity/Q105789233> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q105789233 description "clinical trial" @default.
- Q105789233 description "ensayo clínico" @default.
- Q105789233 description "ensayu clínicu" @default.
- Q105789233 description "klinisch onderzoek" @default.
- Q105789233 description "клінічне випробування" @default.
- Q105789233 description "临床试验" @default.
- Q105789233 name "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 name "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 type Item @default.
- Q105789233 label "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 label "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 prefLabel "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 prefLabel "Abemaciclib, Endocrine Therapy ± Paclitaxel in Aggressive Hormone Receptor (HR)[+]/Human Epidermal Growth Factor Receptor 2 (HER2)[-] Metastatic Breast Cancer (MBC) Trial" @default.
- Q105789233 P1132 Q105789233-CB945B5D-BC37-4B61-914A-3BC7187A9C54 @default.
- Q105789233 P1476 Q105789233-B598BE59-2349-4B4A-9512-7FCC11281E55 @default.
- Q105789233 P1813 Q105789233-88BDF0E0-0FEB-4049-B782-7301D5906A68 @default.
- Q105789233 P2899 Q105789233-745CA438-6D5C-440E-9ACA-3E69F1C5EED5 @default.
- Q105789233 P3098 Q105789233-35026A92-E739-48AA-938D-D476D80C251C @default.
- Q105789233 P31 Q105789233-53D9A211-D3FE-4E2D-B36B-CB6D28DEFAC3 @default.
- Q105789233 P4844 Q105789233-32FC7FCD-991D-48E9-B848-907563F1A11C @default.
- Q105789233 P4844 Q105789233-408189A9-1057-407B-BDC3-786E8C73E6C9 @default.
- Q105789233 P4844 Q105789233-ADEEB8FB-FA58-421C-945D-08284BBC8E82 @default.
- Q105789233 P580 Q105789233-698A4D0B-C23B-4796-9930-6C80534D17DF @default.
- Q105789233 P582 Q105789233-122AF49C-D52C-4F13-ACAF-85B5F5E95FFC @default.
- Q105789233 P6099 Q105789233-21B544C3-227A-4EA0-8973-603C2F7FC6BE @default.
- Q105789233 P767 Q105789233-ED2785B2-A4FE-4085-9EE1-FF7C868ED315 @default.
- Q105789233 P8005 Q105789233-4C4B7EF1-C35F-42D1-95CE-D953C624CC66 @default.
- Q105789233 P8363 Q105789233-C8C585F2-B332-4590-95C3-AF1142D535B2 @default.
- Q105789233 P1132 "+160" @default.
- Q105789233 P1476 "A Randomized, Two-Arm, Open-Label, Phase II Study of Abemaciclib Combined With Endocrine Therapy (Letrozole or Fulvestrant) With or Without a Short Course of Induction Chemotherapy With Paclitaxel as First-Line Therapy in Patients With Unresectable Locally Advanced or Metastatic HR-Positive/HER2-Negative Breast Cancer With Aggressive Disease Criteria" @default.
- Q105789233 P1813 "ABIGAIL" @default.
- Q105789233 P2899 "+18" @default.
- Q105789233 P3098 "NCT04603183" @default.
- Q105789233 P31 Q30612 @default.
- Q105789233 P4844 Q194974 @default.
- Q105789233 P4844 Q423762 @default.
- Q105789233 P4844 Q5508491 @default.
- Q105789233 P580 "2021-02-01T00:00:00Z" @default.
- Q105789233 P582 "2023-02-01T00:00:00Z" @default.
- Q105789233 P6099 Q42824440 @default.
- Q105789233 P767 Q632240 @default.
- Q105789233 P8005 Q76649614 @default.
- Q105789233 P8363 Q78089383 @default.